GlassScriptPhysician profile
Travis Rearick
NPI 1972957132
$7,868.02
in general payments reported to CMS, 2019-2025
41 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $686 · 2021: $858 · 2022: $1,190 · 2023: $1,512 · 2024: $1,768 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,677 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,677.08 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.89 | 2019-2025 | |
| Novo Nordisk INC | $946.20 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $600.61 | 2019-2025 | |
| Lilly USA, LLC | $591.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $545.81 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $415.44 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $374.43 | 2019-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $340.45 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $223.76 | 2019-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $221.27 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $219.74 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amarin Pharma, INC. | $217.73 | 2019-2021 | |
| Allergan, INC. | $216.22 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.79 | 2020-2025 | Jardiance |
| Daiichi Sankyo INC. | $135.01 | 2021-2023 | Injectafer |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.96 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $112.66 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $100.63 | 2022-2023 | Eliquis |
| Astellas Pharma US INC | $95.62 | 2022-2024 | Veozah |
| Dexcom, INC. | $92.75 | 2022-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $77.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $70.55 | 2023 | Dupixent |
| Esperion Therapeutics, INC. | $68.13 | 2021-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $54.55 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.79 | 2023-2024 | Rexulti |
| Stryker Corporation | $45.23 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Abbott Laboratories | $43.34 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Corcept Therapeutics | $31.27 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $27.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.09 | 2019-2020 | |
| Tactile Systems Technology INC | $20.07 | 2025 | Nimbl, Flexitouch Plus |
| Kyowa Kirin, INC. | $16.32 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $15.78 | 2022 | |
| Irhythm Technologies, INC. | $15.42 | 2024 | Zio Xt Patch, Zio Monitor |
| Organon LLC | $15.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.24 | 2023 | |
| Inari Medical, INC. | $15.06 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biohaven Pharmaceuticals, INC. | $14.94 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.86 | 2025 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $13.79 | 2020 | |
| Verona Pharma, INC. | $13.61 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Rearick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.